At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 633 enrolled
Drug / intervention
300 IR (4M) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled, Multi-national, Multi-centre, Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of Two Dosing Regimens of 300 IR Sublingual Immunotherapy (SLIT) Administered as Allergen-based Tablets Once Daily to Patients Suffering From Grass Pollen Rhinoconjunctivitis
In Brief
A Phase 3 clinical trial evaluating 300 IR (4M), 300 IR (2M), and 1 other intervention for Allergy. Completed, enrolled 633 participants across 1 site.
Detailed Summary
A phase III study to evaluate Long term efficacy , carry-over effect and safety of 300 IR sublingual Immunotherapy (SLIT) tablets in adults patients suffering from grass pollen rhinoconjunctivitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergy
CountriesFrance
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2006
First PostedJan 2007
Primary CompletionAug 2010
Study CompletionSep 2011
TodayJul 2026
First PostedJan 4, 2007
Enrollment StartDec 1, 2006
Primary CompletionAug 1, 2010
Study CompletionSep 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 19.5 years ago
Interventions
300 IR (4M)drug
300 IR grass pollen allergen extract tablet starting 4 months before the pollen season
300 IR (2M)drug
300 IR grass pollen allergen extract tablet starting 2 months before the pollen season
Placebodrug
Placebo tablet